| Market Cap | 1.02B | P/E | 102.14 | EPS this Y | -2.00% | Ern Qtrly Grth | -21.70% |
| Income | 9.64M | Forward P/E | 69.01 | EPS next Y | 31.30% | 50D Avg Chg | 11.00% |
| Sales | 66.98M | PEG | 4.32 | EPS past 5Y | -4.57% | 200D Avg Chg | 21.00% |
| Dividend | N/A | Price/Book | 6.01 | EPS next 5Y | 15.00% | 52W High Chg | -24.00% |
| Recommedations | 1.70 | Quick Ratio | 11.73 | Shares Outstanding | 20.01M | 52W Low Chg | 57.00% |
| Insider Own | 18.37% | ROA | 3.63% | Shares Float | 16.32M | Beta | 0.70 |
| Inst Own | 75.11% | ROE | 5.51% | Shares Shorted/Prior | 1.16M/1.34M | Price | 51.07 |
| Gross Margin | 72.53% | Profit Margin | 14.40% | Avg. Volume | 101,696 | Target Price | 57.00 |
| Oper. Margin | 10.14% | Earnings Date | Oct 23 | Volume | 93,257 | Change | 0.77% |
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
| William Blair | Outperform | Sep 12, 24 |
| Keybanc | Overweight | Jul 29, 24 |
| JMP Securities | Market Perform | Jul 16, 24 |
| Craig-Hallum | Buy | Jul 3, 24 |
| William Blair | Outperform | Jun 28, 24 |
| Craig-Hallum | Buy | Jun 13, 24 |
| Oppenheimer | Outperform | Jun 13, 24 |
| Craig-Hallum | Buy | Jan 4, 24 |
| Oppenheimer | Outperform | Jul 7, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| WOLTOSZ WALTER S | Director Director | Feb 01 | Sell | 38.04 | 20,000 | 760,800 | 3,640,195 | 02/05/24 |
| Paglia John Kenneth | Director Director | Jan 04 | Sell | 43.74 | 1,000 | 43,740 | 2,097 | 01/04/24 |
| WOLTOSZ WALTER S | Director Director | Jan 02 | Sell | 44.67 | 20,000 | 893,400 | 3,659,403 | 01/04/24 |
| DiBella John Anthony II | Business Unit Presid.. Business Unit President | Dec 22 | Sell | 45.16 | 5,411 | 244,361 | 79,840 | 12/26/23 |
| DiBella John Anthony II | Business Unit Presid.. Business Unit President | Dec 22 | Option | 19.81 | 5,411 | 107,192 | 85,251 | 12/26/23 |
| WOLTOSZ WALTER S | Director Director | Dec 01 | Sell | 38.79 | 60,000 | 2,327,400 | 3,764,403 | 12/05/23 |
| Paglia John Kenneth | Director Director | Jul 13 | Sell | 46.45 | 1,200 | 55,740 | 2,644 | 07/17/23 |
| WOLTOSZ WALTER S | Director Director | Apr 26 | Sell | 41.8 | 20,000 | 836,000 | 3,875,739 | 04/27/23 |
| DiBella John Anthony II | Division President Division President | Mar 23 | Option | 6.85 | 35,000 | 239,750 | 79,840 | 03/24/23 |
| FREDERICK WILLIAM W | CFO CFO | Mar 02 | Option | 37.89 | 1,875 | 71,044 | 1,875 | 03/06/23 |
| WOLTOSZ WALTER S | Director Director | Feb 24 | Sell | 38.47 | 20,000 | 769,400 | 3,915,739 | 02/27/23 |
| WOLTOSZ WALTER S | Director Director | Jan 27 | Sell | 39.93 | 20,000 | 798,600 | 3,935,010 | 01/31/23 |
| WOLTOSZ WALTER S | Director Director | Nov 28 | Sell | 40.36 | 20,000 | 807,200 | 4,070,010 | 11/29/22 |
| WOLTOSZ WALTER S | Director Director | Oct 27 | Sell | 42.36 | 20,000 | 847,200 | 4,089,307 | 10/31/22 |
| WOLTOSZ WALTER S | Director Director | Sep 28 | Sell | 49.46 | 20,000 | 989,200 | 4,077,907 | 09/29/22 |
| WOLTOSZ WALTER S | Director Director | Aug 29 | Sell | 61.45 | 20,000 | 1,229,000 | 4,097,907 | 08/31/22 |
| WOLTOSZ WALTER S | Director Director | Jul 27 | Sell | 61.25 | 20,000 | 1,225,000 | 4,117,634 | 07/29/22 |
| WOLTOSZ WALTER S | Director Director | Mar 29 | Sell | 48.93 | 20,000 | 978,600 | 4,197,259 | 03/31/22 |
| WOLTOSZ WALTER S | Director Director | Feb 24 | Sell | 37.83 | 20,000 | 756,600 | 4,217,259 | 02/28/22 |
| WOLTOSZ WALTER S | Director Director | Jan 27 | Sell | 39.66 | 20,000 | 793,200 | 4,236,830 | 01/28/22 |
| Paglia John Kenneth | Director Director | Jan 25 | Sell | 40.76 | 600 | 24,456 | 616 | 01/26/22 |
| WOLTOSZ WALTER S | Director Director | Sep 01 | Sell | 44.33 | 1,497 | 66,362 | 4,416,483 | 09/01/21 |
| WOLTOSZ WALTER S | Director Director | Aug 31 | Sell | 44.78 | 18,503 | 828,564 | 4,417,980 | 08/31/21 |
| - | - - | Apr 01 | Sell | 60.24 | 24,000 | 1,445,760 | 4,527,835 | 04/01/21 |
| Paglia John Kenneth | Director Director | Jan 29 | Option | 16.03 | 16,500 | 264,495 | 14,968 | 01/29/21 |
| Paglia John Kenneth | Director Director | Jan 29 | Sell | 80.67 | 17,068 | 1,376,876 | 01/29/21 | |
| WEINER DANIEL L | Director Director | Jan 29 | Option | 24.37 | 4,416 | 107,618 | 9,583 | 01/29/21 |